Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Function Health has launched a secure connector allowing users to feed personalized lab results and clinical notes into mainstream AI chatbots—ChatGPT, Claude, and Perplexity—enabling AI to provide answers grounded in individual biomarkers rather than population averages. This addresses a critical gap: AI health guidance has been generic and contextless, while over 80% of Function's members show at least one biomarker outside optimal ranges that warrant investigation and intervention.
Mito Health, a direct-to-consumer diagnostics platform, has administered over one million tests across seven preventive categories including genomic sequencing, microbiome analysis, advanced imaging, and liquid biopsy screening. The expansion reflects growing demand for accessible, transparent-pricing diagnostic services that operate outside traditional insurance infrastructure.
Veradermics has secured $820 million in funding to advance VDPHL01, an oral extended-release formulation of minoxidil designed to treat pattern hair loss in men and women. The company reports positive Phase 2 data in women and plans confirmatory Phase 3 readouts in men by late 2026, positioning itself to become the first FDA-approved oral, non-hormonal hair loss treatment.
LifespanningRx released the Peptide Explorer, a structured digital questionnaire that maps health goals across ten domains and flags potential peptide therapy candidates for clinician review. The tool screens responses against safety criteria before recommending further evaluation, positioning peptide therapy within a clinician-supervised framework rather than direct-to-consumer access.
GLP-1 receptor agonists extended median lifespan in mice by approximately 14% independent of weight loss, suggesting mechanistic pathways beyond metabolic reduction. This finding positions GLP-1 signaling as a potential longevity intervention with relevance to aging biology beyond diabetes and obesity management.
The Longevity Science Foundation has extended its Invested in Her campaign deadline to October 1, 2026, targeting $250,000 to fund early-stage research into ovarian aging and menopause—a critical gap in women's health science that receives less than 1% of NIH funding despite its systemic impact on cardiometabolic, neurological, and skeletal health across the lifespan.
THPharm is using AI to identify additional therapeutic applications for THP-001, a metabolic drug currently in Phase 3 trials, by analyzing how the compound affects gene expression and biological pathways. This reverse-engineering approach reduces development risk and cost by leveraging existing safety data rather than starting clinical validation from scratch.
Aging-related diseases now represent the dominant global health burden across all income levels and exhibit increasing returns—meaning interventions that reduce one condition simultaneously lower risk for others. This reframing shifts the epidemiological transition from a linear model to one where integrated approaches to aging mechanisms yield compounding benefits.
A monthly research digest covering advances in aging biology, from lifespan extension through amino acid restriction to cellular senescence mechanisms and metabolic interventions. The findings underscore that aging is not a single process but a collection of interconnected cellular and systemic dysfunctions that require multi-targeted approaches for meaningful intervention.
Longevity medicine is expanding faster than clinical standards and practitioner training can support, creating a gap between evidence-based interventions and market-driven products that merely use longevity terminology. Establishing coherent frameworks for practitioner training, diagnostic interpretation, and interdisciplinary care is essential to prevent optimization of unaddressed baseline health problems.
A single endoscopic duodenal ablation procedure maintained approximately 84% of GLP-1-induced weight loss at one year in selected patients, compared to 46% in sham-treated controls. This addresses a significant clinical gap: weight regain after GLP-1 discontinuation, which is common and well-documented.
Thigh muscle fat infiltration, measurable by MRI, associates with increased all-cause mortality and disease across multiple organ systems, with effects mediated by lifestyle factors. Multi-omics analysis identifies 79 genetic variants, specific cell types, tissue-specific gene expression patterns, and circulating biomarkers that mechanistically link muscle composition to systemic health outcomes.